论文部分内容阅读
用ＥＬＩＳＡ法测定３６５例肿瘤患者（包括胃癌、肝癌、胰腺癌、结肠癌、乳腺癌、卵巢癌、肺癌、恶性淋巴瘤、白血病）和２３０例相关脏器的良性疾病患者以及５１名健康人的血清ｓＩＬ－２Ｒ浓度，发现恶性肿瘤患者血清ｓＩＬ－２Ｒ水平明显高于良性疾病患者和健康人对照组（Ｐ＜０．００１），伴转移患者的ｓＩＬ－２Ｒ升高更明显，与不伴转移者相比，差异显著（Ｐ＜０．００１）。作为免疫活性标志，血清ｓＩＬ－２Ｒ可以作为评估肿瘤发生和检测复发的辅助手段。
365 patients with cancer (including gastric cancer, liver cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, lung cancer, malignant lymphoma, leukemia) and 230 patients with benign diseases related to organ and 51 healthy persons were determined by ELISA Serum sIL-2R concentrations found that serum sIL-2R levels were significantly higher in patients with malignant tumors than in patients with benign disease and healthy controls (P < 0.001). Increases in sIL-2R were more pronounced with and without metastases in patients with metastases. The difference was significant (P<0.001). As an immunological marker, serum sIL-2R can be used as an auxiliary means for evaluating tumorigenesis and detecting recurrence.